603590.SH
康辰药业
SSE · Healthcare · Biotechnology · CN
CNY 30.12
−6.49%Year over year
Reported trailing growth
- Revenue
- +9.5%
- EBITDA
- —
- EBIT
- +352.6%
- EPS
- +282.8%
- Free cash flow
- +913.7%
- Operating cash flow
- +75.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.8%
- EBITDA
- +10.9%
- EBIT
- +13.0%
- Net income
- +17.8%
- EPS
- +17.3%
- Free cash flow
- +38.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026